Publication Details

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.

Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. J Clin Oncol. 2009; 27 (3): 418-25

This phase III study tested the hypothesis that the CA-125-specific murine monoclonal antibody, oregovomab, administered as a monoimmunotherapy after front-line therapy in a selected ovarian cancer population would prolong time to relapse (TTR) and, ultimately, survival.

PubMedID: 19075271